Abstract: Axial flow demisting cyclone for separation of material compositions of gas, liquid and particulate solids comprising an inlet conduit (18) for the material composition and an outlet conduit (19) for the substantially dry and clean gas, and a swirl facilitating device (20) that sets the entering material composition in rotation. The cyclons comprises a mainly cylindrical tube (11) which is provided with slots or perforations (21) to allow parts of the material composition, hereunder liquids and particulate solids to flow out from the cyclone tube (11) and into a substantially closed chamber (22) which is delimited by an inlet plate (24), by an outlet plate (23) ad by a circumferential plate (12).

Abstract: The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML. The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans.

Abstract: Vane diffuser for use in separators for separating a liquid phase and/or a particulate material from a gas flow, includes a distribution chamber that communicates with the inlet pipe stub of the separator. A top plate, a bottom plate, and a plurality of curved, parallel vanes together delimit a plurality of diffuser channels. Each of the vanes has a thickness which varies in the flow direction to ensure an even expansion of the cross-sectional area of the diffuser channels, thereby reducing reverse flow along the suction side of the vanes, as occurs with vanes of uniform thickness.

Abstract: This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as ?2 Form, which is stable at room temperature and even at higher temperatures up to 120° C. and accelerated stress conditions and, freely soluble in water. This invention also discloses a pharmaceutical composition containing the novel stable ?2 form of Imatinib mesylate and other usually employed excipients, useful in the treatment of Chronic Myelogenous Leukemia (CML). This new ?2 Form of imatinib mesylate is prepared by slurrying Imatinib base in isopropanol at room temperature followed by addition of methane sulfonic acid and maintaining 50-60 ° C. followed by filtration. This invention also discloses another process for the preparation of the novel, stable ?2 crystalline form of Imatinib Mesylate by the conversion of Imatinib mesylate ?-polymorphic modification by suspending it in water and organic solvents, distilling off water azeotropically, cooling and filtering to obtain the ?2 crystal form.

Abstract: This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through intermediates (3-trifluoromethylsulfonyl)-N-[4-methyl-3-nitrophenyl]-benzamide (formula (III)), (3-trifluoromethylsulfonyl)-N-[3-amino-4-methylphenyl]-benzamide (formula (IV)) and (3-trifluoromethylsulfonyl)-N-[3-guanidino-4-methylphenyl]-benzamide (formula (V)). This invention also relates to processes for the preparation of these intermediates.

Abstract: The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.

Abstract: The present invention relates to an improved pharmaceutical composition, in the form of a soft gel capsule resistant to digestive juice. The composition of the present invention is made up of gelatin and an enteric polymer in the form of free acid or its salt, containing used in the treatment of duodenal ulcers, solublised and/or suspended in a liquid or semisolid medium, comprising the enantiomers of omeprazole such as esomeprazole or rabeprazole or other enantiomers of omeprazole or its salts or derivatives or their mixtures, a hydrophobic carrier, an alkaline inert reacting material and a surface active agent and/or a solublising agent wherein the resulting capsules being insoluble in aqueous medium up to a pH of 5.5 but quickly dissolving above pH of 6.0. The present invention also relates to a process of preparing the above said pharmaceutical composition.

Abstract: The present invention relates to an improved pharmaceutical composition, in the form of a soft gel capsule resistant to digestive juice. The composition of the present invention is made up of gelatin and an enteric polymer in the form of free acid or its salt, containing a benzimidazole derivative used in the treatment of duodenal ulcers, solublised and/or suspended in a liquid or semisolid medium, comprising of a hydrophobic carrier, an alkaline inert to reacting material and a surface active agent and/or a solublising agent. The present invention also relates to a method for preparing the above said pharmaceutical composition.

Abstract: The present invention relates to a novel freeze-dried pharmaceutical composition useful for the treatment of migraine and associated symptoms at a reduced total dose of active substance than required for oral administration in the form of a tablet containing a porous matrix net work of a water soluble or water dispersible carrier material, a pharmaceutically active substance(s); organoleptic additives such as sweetening agents, flavouring agents, coloring agents; pharmaceutically acceptable preservatives; solublising agents; surfaceactive agents and/or buffering agents. The pharmaceutical composition optionally may contain other additives such as permeation enhancers, chelating salts and stabilising agents. The present invention also relates to a process for preparation of the above said composition and its use.

Abstract: This invention relates to an improved process for the preparation of Omeprazole of the formula-I starting from 4-nitro-2,3,5-trimethylpyridine-N-oxide and through novel intermediates 2-hydroxymethyl-3,5-dimethyl-4-nitro pyridine of the formula II and novel 2-chloromethyl-3,5-dimethyl-4-nitro pyridine of the formula III. This invention also relates to processes for the preparation of the above said novel intermediates. Omeprazole is one of the world's widely used drugs for the treatment of ulcer diseases. This compound acts by irreversible inhibition of the H+ K+ ATPase enzyme, which is part of the proton pump located in the parietal cell of the stomach wall.

Abstract: A demisting system used to remove entrained liquid droplets from a gas stream employing radially arranged serpentine vanes. The radial arrangement of the vanes provides flow paths in which the leading edges of the serpentine vanes are closer together than the trailing edges so that a gas stream must undergo a series of direction and velocity changes. Centrifugal forces act to cause liquid droplets to impinge on the surface of the vanes. Surface tension holds the liquid on the vanes as it collects and gravity causes the collected liquid to drain downward and out of the demisting system.

Abstract: An apparatus for separating commingled heavier and lighter immiscible liquids and solids having an upright vessel, a vertical flow tube within the vessel having an upper fluid outlet opening and a lower fluid inlet opening therein, an upper horizontal spreader baffle extending from the flow tube and below the fluid outlet and a lower horizontal spreader baffle extending from the flow tube and above the fluid inlet, a concentric side tube positioned exteriorly of and parallel the vessel and connected to the flow tube below the fluid inlet and providing for the maintenance of a liquid/liquid interface within the vessel above the upper spreader baffle and a commingled fluid inlet pipe extending from exterior of the baffle to the flow tube, the baffle providing means for change of fluid direction from horizontal to vertical and vise versa to improve separation of the lighter from the heavier immiscible liquids and for drawing off both the lighter and the heavier liquids from the vessel.

Abstract: A motorized personal transport vehicle (PTV) with a removable, programmable memory which contains both a key code to enable only an authorized user to operate the PTV and contains constants for use in an algorithm which operates the PTV in accordance with a prescription for that particular user's needs. Control signals from an input, such as a joystick, are modified by the algorithm in accordance with the prescription for a particular user. This prescription is stored in the programmable memory and loaded into the computer when the memory is inserted. The key code in the memory can allow various levels of access, with access for a particular user, a particular group, physician access and technician access. In a preferred embodiment, an electrically erasable programamble read only memory (EEPROM) is used as the memory key.